Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)
CONTRAINDICATIONS
Apidra® is contraindicated during episodes of hypoglycemia and in
patients hypersensitive to Apidra® or any of its excipients.
WARNINGS AND PRECAUTIONS
Closely monitor blood glucose in all patients treated with insulin. Change insulin
regimens cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment. As
with all insulin preparations, the time course of Apidra® action
may vary by individual or at different times in the same individual and is dependent
on many conditions, including the site of injection, local blood supply, or local
temperature.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra®,
which may be serious.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur.
All insulins, including Apidra®, can cause hypokalemia, which if
untreated, may be serious.
A reduction in the Apidra® dose may be required in patients with
renal or hepatic impairment.
Apidra® for subcutaneous injection should not be mixed with insulins
other than NPH. Do not mix Apidra® with any insulin when used in
the pump or for intravenous administration. Insulin devices and needles must not
be shared between patients.
DRUG INTERACTIONS
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and
close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients
taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and
reserpine).
ADVERSE REACTIONS
Other adverse reactions commonly associated with Apidra® include
injection site reactions, lipodystrophy, pruritus, and rash.
Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection) SoloSTAR®
Apidra® SoloSTAR® is a disposable prefilled insulin
pen. To help ensure an accurate dose each time, patients should follow the steps
in the Instruction Leaflet accompanying the pen; otherwise they may not get the
correct amount of insulin, which may affect their blood glucose.
Indications and Usage for Apidra® (insulin glulisine [rDNA origin] injection)
Apidra® is a rapid-acting insulin analog indicated to improve glycemic
control in adults with type 2 diabetes or adults and children (4 years and older)
with type 1 diabetes.
When used as a mealtime insulin, the dose of Apidra®
should be given within 15 minutes before or within 20 minutes after starting a meal.
Apidra® given by subcutaneous injection should normally be used in
regimens that include a longer-acting insulin.
Please
click here for Full Prescribing Information for Apidra®.
Important Safety Information for Lantus® (insulin glargine [rDNA
origin] injection)
CONTRAINDICATIONS
Lantus® is contraindicated in patients hypersensitive to insulin
glargine or one of its excipients.
WARNINGS AND PRECAUTIONS
Monitor blood glucose in all patients treated with insulin. Insulin regimens should
be modified cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.
Do not dilute or mix Lantus® with any other insulin or solution.
If mixed or diluted, the solution may become cloudy, and the onset of action/time
to peak effect may be altered in an unpredictable manner. Do not administer Lantus®
via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin
devices and needles must not be shared between patients.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®,
and may be life-threatening.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur.
A reduction in the Lantus® dose may be required in patients with
renal or hepatic impairment.
DRUG INTERACTIONS
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and
close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients
taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and
reserpine).
ADVERSE REACTIONS
Other adverse reactions commonly associated with Lantus® are injection
site reaction, lipodystrophy, pruritus, and rash.
Indications and Usage for Lantus® (insulin glargine [rDNA
origin] injection)
Lantus® is a long-acting insulin analog indicated to improve glycemic
control in adults and children (6 years and older) with type 1 diabetes mellitus
and in adults with type 2 diabetes mellitus. Lantus® should be administered
once a day at the same time every day.
Important Limitations of Use: Lantus® is not recommended for the
treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.
Please click here for Full Prescribing Information for Lantus®
Click here for information on Sharps Medical Waste Disposal.
*Offer is not valid for patients if their prescriptions are paid in part or
full by any state or federally funded programs, including, but not limited to, Medicare
or Medicaid, Medigap, VA, DOD, or TriCare. Offer is not valid for residents of MA
(except for cash-paying patients) and where prohibited by law. Sanofi US reserves
the right to rescind, revoke, or amend this offer without notice. Maximum benefit
is $100 off per prescription depending on your out of pocket costs. Offer expires
12/31/2012.
